Unraveling resistance to transtuzumab (Herceptin): Insulin-like growth factor-I receptor, a new suspect

Journal of the National Cancer Institute

Volumn 93, Issue 24, 2001, Pages 1830-1832

  Albanell, Joan ^a   Baselga, Jose ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; ANTINEOPLASTIC AGENT; CDKN1B; CELL CYCLE PROTEIN; GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; RECEPTOR, ERBB 2; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RISK; CELL PROLIFERATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; EDITORIAL; FEMALE; HUMAN; HUMAN CELL; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL CULTURE; DRUG RESISTANCE; METABOLISM; NOTE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; DRUG RESISTANCE, NEOPLASM; HUMAN; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0035915283     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.24.1830     Document Type: Editorial

References (29)

1. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
2. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
3. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
4. First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer: A preliminary report
5. Untangling the ErbB signalling network
6. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
7. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
8. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
9. Mechanism of action of anti-HER2 monoclonal antibodies
10. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
11. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
12. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic transduction therapy of solid tumors
13. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
14. The hallmarks of cancer
15. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
16. Targeting the epidermal growth factor receptor: A clinical reality
17. Inhibition by ZD1839 (Iressa) of epidermal growth factor (EGF) and heregulin induced signaling pathways in human breast cancer cells
18. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
19. Small molecule EGF receptor tyrosine kinase Inhibitor ZD1839 (IRESSA) inhibits HER2/neu (erb-2) overexpressing breast tumor cells
20. Cooperative inhibitory effect of ZD1839 ("Iressa") in combination with trastuzumab ("Herceptin") on human breast cancer cell growth
21. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
22. Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer
23. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780
24. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells
25. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
26. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody
27. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis
28. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2
29. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells